{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:55:57Z","timestamp":1775292957020,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Gastrointestinal Oncology Society (GIOD)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ejca.2011.10.011","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T15:55:31Z","timestamp":1321545331000},"page":"279-285","source":"Crossref","is-referenced-by-count":11,"title":["Hepatotoxicity associated with lapatinib in an experimental rat model"],"prefix":"10.1016","volume":"48","author":[{"given":"Umut","family":"Demirci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman","family":"Buyukberber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guldal","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aytug","family":"Uner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meltem","family":"Baykara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatice","family":"Pasali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Benekli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.10.011_b0005","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdg365","article-title":"Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer","volume":"14","author":"Atalay","year":"2003","journal-title":"Ann Onc"},{"key":"10.1016\/j.ejca.2011.10.011_b0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/bcr51","article-title":"Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases","volume":"2","author":"Stern","year":"2000","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2011.10.011_b0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ejca.2006.10.020","article-title":"Progress and new standards of care in the management of HER-2 positive breast cancer","volume":"43","author":"Demonty","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2011.10.011_b0020","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ejca.2011.10.011_b0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2011.10.011_b0030","first-page":"3","article-title":"The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients","volume":"13","author":"Klijn","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejca.2011.10.011_b0035","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.10.011_b0040","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.10.011_b0045","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.10.011_b0050","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2011.10.011_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V","article-title":"Specificity within the EGF family\/ErbB receptor family signaling network","volume":"20","author":"Riese","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.ejca.2011.10.011_b0060","doi-asserted-by":"crossref","first-page":"30934","DOI":"10.1074\/jbc.M004112200","article-title":"Akt\/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation","volume":"275","author":"Okano","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2011.10.011_b0065","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"55","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.10.011_b0070","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/dmd.107.018374","article-title":"The role of efflux and uptake transporters in N-{3-chloro-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2(methylsulfonyl) ethyl] amino}methyl)-2-furyl]-4quinazolinamine(GW572016, lapatinib) disposition and drug interactions","volume":"36","author":"Polli","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejca.2011.10.011_b0075","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/bjs.5719","article-title":"Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases","volume":"94","author":"Zorzi","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2011.10.011_b0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejso.2006.11.022","article-title":"Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month","volume":"34","author":"Schouten van der Velden","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncponc1087","article-title":"Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy","volume":"5","author":"Loriot","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0090","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2011.10.011_b0095","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cncr.23099","article-title":"Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases","volume":"110","author":"Ribero","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.10.011_b0100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2008.12.013","article-title":"Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX\/FOLFOX therapy of colorectal cancer liver metastases","volume":"35","author":"Klinger","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0105","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","article-title":"Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases","volume":"30","author":"Medina","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejca.2011.10.011_b0110","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas","volume":"23","author":"Burris","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0115","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/sj.bjc.6605343","article-title":"Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies","volume":"10","author":"Toi","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2011.10.011_b0120","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1200\/jco.2009.27.15_suppl.1043","article-title":"Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib","volume":"27","author":"Moy","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","article-title":"HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer","volume":"29","author":"Spraggs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.meg.0000216941.42306.0e","article-title":"Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour","volume":"18","author":"Pariente","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2011.10.011_b0135","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.10.011_b0140","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2003-07-2323","article-title":"Fatal hepatic necrosis following imatinib mesylate therapy","volume":"102","author":"Lin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.10.011_b0145","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/sj.leu.2402702","article-title":"Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis","volume":"16","author":"Ohyashiki","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2011.10.011_b0150","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1200\/JCO.2004.00.6650","article-title":"Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib","volume":"23","author":"Ho","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0155","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1158\/0008-5472.CAN-06-3559","article-title":"Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor","volume":"67","author":"Jani","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.10.011_b0160","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/S0024-3205(03)00699-4","article-title":"Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of the multidrug resistance protein 2 (Mrp2)","volume":"73","author":"Jager","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.ejca.2011.10.011_b0165","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1200\/JCO.2006.07.9244","article-title":"Benefits and risks of neoadjuvant therapy for liver metastases","volume":"24","author":"Nordlinger","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0170","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"Aloia","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0175","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejso.2007.09.007","article-title":"Effect of preoperative chemotherapy on liver resection for colorectal liver metastases","volume":"34","author":"Mehta","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2011.10.011_b0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2011.10.011_b0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911007982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911007982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:23:26Z","timestamp":1639700606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911007982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0959804911007982"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.10.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}